PRODUCT INFORMATION

Name of the Medicine

Active ingredient: Bromocriptine mesylate.

Chemical name: Bromocriptine BAN is 2-bromo-\(\alpha\)-ergocryptine.

Structural formula

![Structural formula of Bromocriptine mesylate]

Molecular formula: \(\text{C}_{32}\text{H}_{48}\text{BrN}_{6}\text{O}_{5}\text{CH}_{2}\text{O}_{3}\text{S}\)

The molecular weight of the free base is 654.5 and that of the mesylate salt 750.6

CAS Registry No.: 22260-51-1

Description

Bromocriptine mesylate is a peptide ergot alkaloid, poorly soluble in water (<0.1% at 20-25°C). Solubility in ethanol (70% v/v) is 75%.

Kripton 2.5 tablets contains 2.5 mg of the active ingredient bromocriptine mesylate and the following inactive ingredients: lactose, starch-maize, silica-colloidal anhydrous, maleic acid, disodium edetate and magnesium stearate.

Kripton 5 and Kripton 10 capsules contain 5 mg and 10 mg, respectively, of the active ingredient bromocriptine mesylate. The capsules also contain the following inactive ingredients: lactose, starch-maize, silica-colloidal anhydrous, maleic acid, magnesium stearate, sodium lauryl sulfate, gelatin, titanium dioxide, iron oxide black, allura red AC, TekPrint SW-9008 Black Ink and TekPrint SW-9009 Black Ink.

Pharmacology

Bromocriptine has a pharmacological spectrum unlike that of most classical ergot compounds, having no uterotonic and little vasoconstrictor activity. Its principal effects derive from dopaminergic receptor stimulant activity. It inhibits prolactin secretion and the effect can be demonstrated after single or repeated oral administration of the drug. Moreover, the effect is relatively specific in that doses necessary to produce inhibition of prolactin secretion do not interfere with release of gonadotrophins or thyrotropin. However, bromocriptine elevates growth hormone for a few hours after each dose in normal or diabetic persons. This may not be reflected by an elevation of basal levels during chronic administration. However, it may suppress the elevated growth hormone levels of acromegalic patients.
Bromocriptine has been shown to arrest the growth or to reduce the size of prolactin-secreting pituitary adenomas (prolactinomas).

Pharmacological investigations in rodent brains show that in addition to its effects at the hypothalamic-pituitary axis, bromocriptine exerts CNS activity primarily via post-synaptic dopamine receptor activation in the corpus striatum. Bromocriptine can therefore be used in Parkinson's disease.

Clinical Effects

Hyperprolactinaemia
Prolactin secretion is controlled by the hypothalamic tuberoinfundibular dopaminergic neurone system, which releases either dopamine or a prolactin inhibiting factor (PIF) into the hypothalmo-hypophyseal portal system to suppress the secretion of prolactin by the pituitary. Bromocriptine has been shown to mimic this action of dopamine on the pituitary prolactin cells and to act also at the hypothalamic level.

Prolactin is the crucial hormone for the preparation of the mammary gland for lactation and for the initiation and maintenance of milk secretion. During pregnancy and after childbirth (through suckling stimuli) prolactin levels are elevated. Reduction of circulating prolactin levels will thus prevent or suppress lactation. In some conditions the secretion of prolactin may become elevated in situations unconnected with pregnancy and childbirth. Such nonphysiological hyperprolactinaemia may mimic the postpartum situation by inducing amenorrhoea and/or lactation (galactorrhoea). In healthy women prolactin does not seem to be involved in the normal cycle of gonadotrophin secretion and ovarian functions. But in conditions favouring prolactin secretion, the regular cyclic gonadotrophin and gonadal steroid secretion become attenuated and are eventually suppressed. Bromocriptine, through its dopaminergic activity, returns prolactin levels towards normal and either enhances the release of gonadotrophic hormones or restores the sensitivity of the ovary to gonadotrophic stimulation. Hence galactorrhoea and amenorrhoea are interrupted and menses return.

Apparent regression in tumour size has been documented in a number of patients with prolactin-secreting adenomas.

Acromegaly
In about 50% of acromegalic patients, bromocriptine reduced the elevated growth hormone level to half of pretreatment levels or below. In acromegaly bromocriptine has a beneficial effect on clinical symptoms, such as headaches, sweating, acral features, ring and shoe size, hypertension and glucose tolerance, although this may not be clearly correlated with a change in growth hormone levels. Overall about 50% of patients have shown clinical improvement to bromocriptine. Of the remaining patients many have a significant fall in growth hormone levels, not associated with improvements in clinical symptoms.

There are no data on the effect of bromocriptine on tumour size in acromegaly or on the functional capacity of the tumour. There is some evidence that the acromegalic process resumes on cessation of therapy.

Parkinson's disease
This disorder is characterised by progressive deficiency in dopamine synthesis in the substantia nigra. Bromocriptine produces its therapeutic effect by directly acting on dopamine receptors in the corpus striatum mimicking an increased supply of endogenous dopamine. In clinical studies bromocriptine has been as effective as levodopa alone or in combination with decarboxylase inhibitors. Combination with levodopa may allow a reduction in the dosage of either compound. Bromocriptine is useful in patients with a deteriorating response to levodopa or suffering from the "on-off" phenomena. Bromocriptine may be given alone in mild, early cases, or in combination with anticholinergic drugs and/or other antiparkinson drugs. However, data are not yet sufficient to evaluate the role of bromocriptine in treating early Parkinsonism.

Pharmacokinetics

Absorption
In rats, rabbits, monkeys and man, bromocriptine has been shown to be rapidly absorbed after oral administration. In man the absorption half-life from the oral tablet formulation determined by radioimmunoassay is approximately 0.3 hours. About 7% of the dose reaches the systemic circulation unchanged. This is due to a high hepatic extraction rate and first pass metabolism. The studies were done on fasting subjects. There are no studies on the effect of food on bioavailability but clinical experience suggests that absorption is satisfactory when bromocriptine is taken in the recommended way, i.e. with meals.

Distribution
Two hours after oral administration of $^3$H-bromocriptine in the rat, radioactivity was found in all organs with highest values in the liver, stomach and intestine. Plasma protein binding amounts to 96%.
**Metabolism**
In man, the substance is extensively metabolised by the liver. Only traces of the unchanged compound were found in urine, with 2 major metabolites. Unchanged drug represents about 10-15% of peak levels of radioactivity in plasma measured after single doses of labelled drug. It is not known whether the metabolites are pharmacologically active in man; however, the two main urinary metabolites, 2-bromolysergic acid and 2-bromoisoxysergic acid have negligible pharmacological activity in animals.

**Excretion**
The active parent drug and the metabolites are excreted primarily via the liver into the bile; only 6% is eliminated via the kidney. After single oral doses, the mean elimination half-life from plasma varies from 2 to 8 hours for the parent drug and 50 to 73 hours for the metabolites.

On repeated dosing, bromocriptine accumulates to the extent that plasma concentrations may be about twice those observed after single doses. Although there are no data on the accumulation of metabolites, their much longer half-life indicates that steady state plasma concentrations, which are about ten times greater than those observed after single doses, should be reached in approximately 10 days.

**Indications**
1) Prevention of onset of lactation in the puerperium for clearly defined medical reasons. Therapy should be continued for 14 days to prevent rebound lactation. Kripton should not be used to suppress established lactation.

2) Treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. Precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. Where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, bromocriptine is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated.

3) Adjunctive therapy in the management of acromegaly when:-
   (i) the patient refuses surgery and/or radiotherapy;
   (ii) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months;
   (iii) a manifestation of the acromegaly needs to be brought under control pending surgery and/or radiotherapy.

4) Idiopathic or post-encephalitic Parkinson's disease. It should be noted that data are not yet sufficient to evaluate the role of bromocriptine in treating early Parkinsonism.

**Contraindications**
1. Hypersensitivity to bromocriptine or other ergot alkaloids; hypersensitivity to any other components of the formulation.
2. Uncontrolled hypertension, toxaemia, hypertensive disorders of pregnancy (including eclampsia, pre-eclampsia or pregnancy induced hypertension), hypertension postpartum and in the puerperium. For procedure during pregnancy see Use in Pregnancy.
3. Coronary artery disease and other severe cardiovascular conditions.
4. Symptoms and/or history of serious psychiatric disorders.

**Precautions**

**Use in Pregnancy (Category A)**
Over 2,400 women are recorded as having taken bromocriptine during part of pregnancy. The reported incidence of congenital malformations and spontaneous abortions within this group of pregnancies did not exceed that generally reported in the population at large. Postnatal development was studied in more than 900 children exposed to bromocriptine in utero. One hundred and five of these children were exposed throughout pregnancy. No specific pattern of abnormal postnatal development could be recognised.
In patients wishing to conceive however, bromocriptine, like all drugs should be discontinued when pregnancy is confirmed, unless there is a medical reason for continuing.

**Fertility**

In patients being treated with bromocriptine for hyperprolactinaemic conditions, fertility is commonly restored. The return of ovulation post-partum also may be hastened. Thus, women who do not wish to conceive should take contraceptive measures in order to prevent an unintended pregnancy.

If women with conditions not associated with hyperprolactinaemia are treated with bromocriptine, the drug should be given in the lowest effective dose necessary to relieve the symptoms; this is in order to avoid the possibility of suppressing plasma prolactin below normal levels, with a consequent impairment of luteal function.

In women wishing to conceive, the cause of sterility and a search for pituitary adenoma should be made before starting bromocriptine treatment. Pregnancy must be avoided if a significant or expanding pituitary adenoma is diagnosed. However, if pregnancy occurs in the presence of a pituitary adenoma and bromocriptine treatment has stopped, close supervision throughout pregnancy is essential. In patients who show symptoms of a pronounced enlargement of a prolactinoma, e.g. headache or visual field deterioration, bromocriptine treatment may be re instituted. In other cases, surgery may be considered appropriate.

In the absence of a significant or expanding pituitary adenoma and if the patient wishes to conceive, bromocriptine should be stopped as soon as possible after conception.

**Established pregnancy**

In cases of established pregnancy - as a precautionary measure – possible untoward effects of pituitary enlargement associated with pregnancy should be sought regularly, for instance, by checking the visual fields.

**Use in Lactation**

Since it prevents lactation, bromocriptine should not be administered to mothers who wish to breast-feed.

**Physiological lactation**

In rare cases, serious adverse reactions have been reported, including seizures, stroke, myocardial infarction, hypertension and psychic disorders. Seizures were not necessarily accompanied by the development of hypertension. An unremitting and often progressively severe headache, sometimes accompanied by visual disturbance (blurred vision, and transient cortical blindness), often preceded by hours to days the occurrence of seizure and/or stroke. Most patients had shown no evidence of toxaemia during the pregnancy.

Although the relationship of these adverse reactions to bromocriptine administration is not certain, periodic monitoring of blood pressure is advisable in post-partum women receiving bromocriptine for the inhibition of lactation as well as in patients treated for any other condition. The use of bromocriptine is contraindicated in patients with uncontrolled hypertension, coronary artery disease, toxaemia of pregnancy or symptoms and/or a history of serious psychic disorders.

Particular attention should be paid to patients who have recently received or are on concomitant therapy with other drugs that can alter the blood pressure, e.g. vasoconstrictors such as sympathomimetics or ergot alkaloids, including ergometrine. Although there is no conclusive evidence which demonstrates the interaction between bromocriptine and these other drugs, the concomitant use of these medications in the puerperium is not recommended.

Bromocriptine therapy for the inhibition of lactation should not be initiated until the vital signs have been stabilised and no sooner than four hours after delivery, as bromocriptine is known to produce hypotension, and rarely hypertension, in some patients. Because the development of hypertension may be delayed, the blood pressure should be monitored periodically during the first weeks of therapy. If hypertension, severe, progressive or unremitting headache (with or without visual disturbance), or evidence of CNS toxicity develops, drug therapy should be discontinued and the patient should be evaluated promptly.

**Psychiatric disturbances**

Bromocriptine administered alone or concomitantly with levodopa for Parkinson's disease may cause hallucinations (visual or auditory), which usually resolve with dosage reduction; occasionally, discontinuation of bromocriptine is required. Rarely, after high doses, hallucinations have persisted for several weeks following discontinuation of bromocriptine. High doses of bromocriptine may be associated with confusion and mental disturbances. Since parkinsonian patients may manifest mild degrees of dementia, caution should be used when treating such patients.
Compulsive behaviour
Compulsive behaviour such as gambling, hypersexuality, shopping, eating, medication use and punding (repetitive purposeless activity) has been reported in patients taking dopamine agonists for the treatment of Parkinson's disease, especially at high doses. Prescribers, patients and caregivers should be alert to the possibility of such behaviour, which may have serious financial and social consequences.

Hypotension
Bromocriptine is known to cause hypotension in some subjects. This usually manifests as postural hypotension and may be more common during initial dosing. Occasional reports have been made of collapse with hypotension and loss of consciousness within a few hours of taking initial doses of 1.25 to 2.5 mg.

For these reasons treatment should be initiated with small doses and great care in all patients and especially in those with compromised cerebral or cardiac circulation. In post-partum patients hypotension independent of drug therapy may already be present and bromocriptine therapy for suppression of lactation should not be commenced until vital signs are stable and no sooner than four hours after delivery.

Although there is no evidence of an interaction with antihypertensive agents, care should be exercised if bromocriptine is administered with other medication known to lower blood pressure.

Tumourigenicity
A lifetime rat study revealed that some animals developed uterine tumours and endometrial carcinoma thought to be due to a state of induced oestrogen dominance. However, clinical experience in women with a variety of hyperprolactinaemic and other conditions, treated with bromocriptine for months and in some cases for years, failed to demonstrate abnormal trends in hormonal levels or in endometrial cytology.

Gynaecological supervision
Although there is no evidence of uterine tumour development in women receiving bromocriptine, in view of the above-mentioned life-time rat study, it is recommended that female patients on long term therapy should have regular gynaecological assessments (see Precautions - Tumourigenicity).

Prolactin-secreting adenomas
In some patients with macroprolactinoma, secondary deterioration of the visual fields may develop despite normalised prolactin levels and tumour shrinkage. This may result from traction on the optic chiasm, which is pulled down into the now partially empty sella. In these cases, the visual field defect may improve on reduction of Kripton dosage, while there is some elevation of prolactin and some tumour re-expansion. Monitoring of visual fields in patients with macroprolactinoma is recommended to allow early recognition of secondary loss of visual fields due to chiasmal herniation of drug dosage.

If pregnancy occurs in patients with adenomas after the administration of Kripton, careful observation is mandatory (see Precautions - Fertility).

In some patients with prolactin-secreting adenomas treated with bromocriptine, cerebrospinal fluid rhinorrhea has been observed.

Peptic ulcer
Patients with suspected or known peptic ulceration should be treated cautiously in view of several reports of fatal gastric haemorrhage in acromegalic patients, given high doses of bromocriptine. No causal relationship has been established between bromocriptine treatment and these findings and gastric haemorrhage is known to occur in acromegalic patients. If bromocriptine must be used in such patients, they should be instructed to report any gastrointestinal side effects. If gastrointestinal bleeding or gastric ulceration occurs, Kripton should be withdrawn.

CNS effects
Bromocriptine can have unwanted central actions such as dizziness, syncope, confusion, and hallucinations and particular care should, therefore, be exercised by patients driving vehicles, operating dangerous machinery, or being pedestrians in busy areas.

Bromocriptine has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson's disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with bromocriptine. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines. Furthermore, a reduction of dosage or termination of therapy may be considered.
Diabetic retinopathy
Bromocriptine may cause a release of growth hormone in normal and diabetic patients, lasting 1-2 hours. Growth hormone has been implicated in the acceleration or maintenance of diabetic retinopathy, and bromocriptine should, therefore, be used with caution in patients with diabetes.

Pleuropulmonary changes
Long-term treatment with bromocriptine for Parkinson's disease has been associated with pleural and pericardial effusions, as well as pleural and pulmonary fibrosis and constrictive pericarditis. If long-term treatment is required, physicians should consider regular monitoring e.g. chest x-rays. Patients presenting with unexplained pleuropulmonary signs or symptoms should be examined thoroughly and discontinuation of bromocriptine therapy should be contemplated.

Retroperitoneal fibrosis
Retroperitoneal fibrosis has been reported in a few parkinsonian patients who were treated over years with bromocriptine at daily doses higher than 30 mg. To recognise retroperitoneal fibrosis at an early, reversible stage, it is recommended that its manifestations (e.g. back pain, oedema of the lower limbs, impaired kidney function) be looked for in this category of patient. Bromocriptine should be withdrawn if fibrotic changes in the peritoneum are diagnosed or suspected.

Liver function
The extensive hepatic metabolism of bromocriptine suggests that patients with impaired hepatic function should be treated with care. Dose adjustment may be required.

Galactose intolerance
Patients with rare hereditary problems of galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption should not take bromocriptine.

Children
The use of bromocriptine is not recommended for children.

Effects on Ability to Drive and Operate Machinery
Patients being treated with bromocriptine and presenting with somnolence and/or sudden sleep episodes must be informed to refrain from driving or engaging in activities where impaired alertness may put themselves or others at risk of serious injury or death (e.g. operating machines) until such recurrent episodes and somnolence have resolved (see Precautions - CNS effects).

Since, especially during the first days of treatment, hypotensive reactions may occur and result in decreased alertness, particular care should be exercised when driving a vehicle or operating machinery (see Precautions - Hypotension).

Interactions with Other Medicines
Tolerability to bromocriptine may be reduced by alcohol.

The hypotensive effects of bromocriptine may be additive with those of drugs used to treat hypertension and other medication known to lower blood pressure.

Bromocriptine is both a substrate and an inhibitor of CYP3A4. Caution should therefore be used when co-administering drugs which are strong inhibitors and/or substrates of this enzyme (azole antimycotics, HIV protease inhibitors).

The concomitant use of erythromycin, other macrolide antibiotics, or octreotide has been shown to increase bromocriptine plasma levels. The bioavailability of bromocriptine increased by approximately 40% when it was administered together with octreotide.

For the concomitant use of sympathomimetic drugs in post-partum women, see Precautions - Physiological lactation.

Pharmacological considerations indicate there are a number of theoretically possible drug interactions. Since bromocriptine exerts its therapeutic effect by stimulating central dopamine receptors, dopamine antagonists such as antipsychotics (phenothiazines, butyrophenones and thioxanthenes), but also metoclopramide and domperidone may reduce its activity. The following drugs may increase prolactin secretion and possibly may
antagonise bromocriptine in a dose dependent manner: phenothiazines; butyrophenones; metoclopramide; methyldopa; reserpine; tricyclic antidepressants; pimozide; oestrogens; TRF. Other drugs may inhibit prolactin release from the pituitary and may be synergistic with bromocriptine: levodopa; clonidine; pargyline; iproniazid.

**Adverse Effects**

During the first days of treatment patients commonly experience nausea, dizziness or headache and less frequently nasal congestion, fatigue, or vomiting, not usually sufficiently serious to require treatment to be discontinued. Bromocriptine frequently causes a reduction in blood pressure, manifested as postural hypotension (very rarely leading to syncope).

The spectrum and incidence of side effects occurring in Parkinson's patients differs somewhat from that found in patients being treated for endocrinological indications. It should be noted that to date clinical experience of bromocriptine in Parkinson's disease has generally followed or been associated with other therapy. Hallucinations, confusion and behavioural disturbances have been reported commonly in patients receiving doses above 15 mg/day. Delusions, psychotic episodes (including paranoia) and delirium are less frequent. Psychotic episodes have also occurred at 2.5 to 5.0 mg daily. Dyskinesias or abnormal involuntary movements and "on-off" effect have been reported in patients treated for Parkinson's disease, but to date there is no adequate experience of patients who have been treated only with bromocriptine. Pleuro-pulmonary changes (pleural and pericardial effusions, pleural and pulmonary fibrosis), constrictive pericarditis and retroperitoneal fibrosis have occurred in patients on long term therapy. (See **Precautions**).

In several acromegalic patients treated with high doses, fatal gastric haemorrhage has been reported. (See **Precautions**).

Episodes of reversible pallor of the fingers and toes induced by cold have occasionally been reported during prolonged treatment, particularly in patients previously exhibiting Raynaud's phenomenon.

The use of bromocriptine for the inhibition of physiological lactation postpartum has been associated with the rare occurrence of hypertension, myocardial infarction, seizures, stroke and psychiatric disorders. (See **Contraindications** and **Precautions**.)

Drowsiness, nasal congestion, constipation, fatigue and less frequently psychomotor excitation, ataxia, insomnia, depression, anorexia, visual disturbances, dyskinesia, dryness of the mouth, erythromelalgia and leg cramps, metallic taste, decreased alcohol tolerance, diplopia, eye discomfort, tachycardia, bradycardia, cardiac arrhythmias, epigastric / abdominal pain, gastrointestinal ulcer, oedema, peripheral oedema, urticaria and other rashes, tiredness, hair loss, paraesthesia, tinnitus, pleurisy, dyspnoea and a burning sensation in the breast have also been reported. These side effects are usually dose dependent and can in most cases be controlled by a reduction in dosage.

There have been very rare reports of a syndrome resembling Neuroleptic Malignant Syndrome (NMS) on abrupt withdrawal of bromocriptine.

There have been very rare reports of cardiac valve fibrosis.

Bromocriptine is associated with somnolence and has been associated very rarely with excessive daytime somnolence and sudden sleep onset episodes (see **Precautions - CNS effects**).

Patients treated with dopamine agonists for treatment of Parkinson’s disease, including bromocriptine, especially at high doses, have been reported as exhibiting signs of pathological gambling, increased libido and hypersexuality, generally reversible upon reduction of the dose or treatment discontinuation.

**Dosage and Administration**

The drug should always be taken with food since the incidence of nausea is reduced.

**Inhibition of physiological lactation**

2.5 mg (1 tablet) twice daily, with morning and evening meals, for 14 days. To prevent the onset of lactation treatment should be commenced as soon as possible after parturition but not until vital signs, especially blood pressure, have stabilised and not until four hours after delivery (see **Precautions - Hypotension**). Secretion of milk may recur 2 to 3 days after the end of the treatment period. This can be controlled by resuming treatment at the same dosage for a further week.
Hyperprolactinaemia
1.25 mg (½ tablet), 2 to 3 times daily. If this proves inadequate, gradually increase to 2.5 mg (1 tablet), 2 or 3 times daily with meals. If associated with galactorrhoea, continue treatment until breast secretion has completely disappeared and if associated with amenorrhoea, until the menstrual cycle has returned to normal. If required treatment may be continued over several menstrual cycles to prevent relapse. For the treatment of prolactinomas, bromocriptine should be initiated at 1.25 mg (½ tablet) 2 times daily. If the dosage proves inadequate to reduce the serum prolactin level and reduce tumour size, gradually increase up to 15 mg daily in divided doses.

Adjunctive therapy in the management of acromegaly
Initially 1.25 mg (½ tablet) at night, increasing gradually over a period of 1 to 2 weeks to 10 mg daily. Most acromegalics able to derive benefit from bromocriptine do so at doses of 10 to 30 mg daily. Dosage should be adjusted appropriately depending on clinical response and side effects. The daily dose should be taken in four equally divided doses with meals. It is recommended that a daily dose of 40 mg is not exceeded.

Parkinson's disease
Anti-Parkinson effects can be obtained with doses as low as 5-10 mg daily. The therapeutic range in either mono- or combined therapy is 5-40 mg/day in divided doses, usually at 6-8 hourly intervals. The best results may be achieved if the dosage is increased slowly, starting with 1.25 mg (½ tablet) once or twice a day (with meals) for the first week, followed by increments of not more than 1.25 mg every week as monitored by therapeutic response and tolerability. When bromocriptine is given in combination with levodopa, with or without decarboxylase inhibitor, it may be possible to reduce the dose of levodopa; any reduction in the dosage should be gradual. In certain cases levodopa can be withdrawn completely.

Overdosage
There have been isolated reports of children who accidentally ingested bromocriptine. Vomiting, somnolence and fever were reported as adverse events. Patients recovered either spontaneously within a few hours or after appropriate management.

Several reports have been made of acute overdosage with bromocriptine which, however, were mainly within the therapeutic range. There were no life-threatening reactions. Symptoms reported could have resulted from overstimulation of dopaminergic receptors. They include nausea, vomiting, dizziness, drowsiness, lethargy, somnolence, tachycardia, hypotension and postural hypotension. In addition psychotic reactions and hallucinations may also occur. Metoclopramide may be of value in antagonising some of the symptoms of bromocriptine overdosage.

Contact the Poisons Information Centre on 131126 (Australia) for advice on the management of overdosage.

Presentation and Storage Conditions

**Kripton 2.5**  Bromocriptine 2.5 mg tablet (present as 2.9 mg mesylate): white, coded “BE” and “2.5” above and below the scoreline, respectively, on one side and “α” on the other side; 30s, 60s.

**Kripton 5**  Bromocriptine 5 mg capsule (present as 5.735 mg mesylate): grey body coded “BE 5”, red cap coded “α” on the other side; 60s.

**Kripton 10**  Bromocriptine 10 mg capsule (present as 11.5 mg mesylate): yellow body coded “BE 10”, red cap coded “α” on the other side; 100s.

Tablets : Store below 25°C. Protect from light.

Capsules : Store below 30°C.
Poison Schedule of the Medicine

Schedule 4 (Prescription Only Medicine)

Name and Address of the Sponsor

Alphapharm Pty Limited
Chase Building 2
Wentworth Park Road
Glebe NSW 2037

ABN 93 002 359 739

www.alphapharm.com.au

Date of Approval

Approved by the Therapeutic Goods Administration on 21 September 1999.
Date of most recent amendment: 12 August 2008.